APA (7th ed.) Citation

V, D. C., E, C., HA, N., J, C., K, P., D, D., . . . ME, H. (2025). Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer's disease drug candidate CT1812. Alzheimer's & dementia (New York, N. Y.), 11(2), e70119. https://doi.org/10.1002/trc2.70119

Chicago Style (17th ed.) Citation

V, Di Caro, et al. "Identification of Cerebrospinal Fluid Pharmacodynamic Biomarkers and Molecular Correlates of Brain Activity in a Phase 2 Clinical Trial of the Alzheimer's Disease Drug Candidate CT1812." Alzheimer's & Dementia (New York, N. Y.) 11, no. 2 (2025): e70119. https://doi.org/10.1002/trc2.70119.

MLA (9th ed.) Citation

V, Di Caro, et al. "Identification of Cerebrospinal Fluid Pharmacodynamic Biomarkers and Molecular Correlates of Brain Activity in a Phase 2 Clinical Trial of the Alzheimer's Disease Drug Candidate CT1812." Alzheimer's & Dementia (New York, N. Y.), vol. 11, no. 2, 2025, p. e70119, https://doi.org/10.1002/trc2.70119.